StockNews.com Begins Coverage on BioLineRx (NASDAQ:BLRX)

Stock analysts at StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright cut their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 25th.

BioLineRx Price Performance

BLRX stock opened at $0.14 on Friday. The firm has a 50 day simple moving average of $0.29 and a two-hundred day simple moving average of $0.51. The stock has a market cap of $11.42 million, a PE ratio of -0.65 and a beta of 1.46. BioLineRx has a one year low of $0.14 and a one year high of $1.52. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37.

Institutional Trading of BioLineRx

Hedge funds have recently bought and sold shares of the company. PVG Asset Management Corp bought a new position in BioLineRx during the second quarter valued at approximately $70,000. Atria Investments Inc boosted its stake in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares in the last quarter. Finally, CVI Holdings LLC bought a new position in shares of BioLineRx during the 2nd quarter valued at $462,000. Institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.